Oral epigallocatechin gallate reduces intestinal nadolol absorption via modulation of Oatp1a5 and Oct1 transcriptional levels in spontaneously hypertensive rats

Hong-Jie Tan,Wei-Chih Ling,Ang-Lim Chua,Siew-Keah Lee

DOI: https://doi.org/10.1016/j.phymed.2021.153623

IF: 6.656

2021-09-01

Phytomedicine

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Concurrent use of epigallocatechin-3-gallate (EGCG) and medication may lead to botanical-drug interactions, subsequently therapeutic failure or drug toxicity. It has been reported that EGCG reduces plasma nadolol bioavailability in normotensive models. Nevertheless, evidence on the effects of EGCG on hypertensive model, and the possible underlying mechanism have not been elucidated.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objectives</h3><p>This study aims (i) to investigate the effects of EGCG on nadolol pharmacokinetics (maximum plasma concentration, time to achieve maximum concentration, area under the time-plasma concentration curve, plasma half-life and total clearance) and subsequently its impact on blood pressure control; and (ii) to identify transcriptional regulatory roles of EGCG on the nadolol intestinal and hepatic drug-transporters in SHR.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>Male SHR were pre-treated with a daily dose of EGCG (10 mg/kg body weight, i.g.) for 13 days. On day-14, a single dose of nadolol (10 mg/kg body weight) was given to the rats 30 minutes after the last dose of EGCG administration. Systolic blood pressure (SBP) was measured at 6-h and 22-h post-nadolol administration. Plasma and urinary nadolol concentrations were quantified using high-performance liquid chromatography, and pharmacokinetic parameters were analyzed by using non-compartmental analysis. Hepatic and ileal <em>Oatp1a5, P-gp</em>, and <em>Oct1</em> mRNA expressions were determined by real-time PCR.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>SBP of SHR pre-treated with EGCG and received nadolol was significantly higher than those which were not pre-treated with EGCG but received nadolol. Pre-treatment of EGCG resulted in a marked reduction of plasma nadolol maximum concentration (C_max) and area under the time-plasma concentration curve (AUC) by 53% and 51% compared to its control. The 14-day treatment with oral EGCG led to a significant downregulation of mRNA levels of ileal <em>Oatp1a5, P-gp,</em> and <em>Oct1</em> genes by 4.03-, 8.01- and 4.03-fold; and hepatic <em>P-gp,</em> and <em>Oct1</em> genes by 2.61- and 2.66-fold.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>These data concluded that exposure to EGCG could lead to reduced nadolol bioavailability and therefore, uncontrolled raised blood pressure and higher risks of cardiovascular events. Our data suggest that the reduced nadolol bioavailability is associated with the downregulation of ileal <em>Oatp1a5</em> and <em>Oct1</em> mRNA levels that subsequently lead to poor absorption of nadolol to the systemic circulation.</p>

pharmacology & pharmacy,chemistry, medicinal,integrative & complementary medicine,plant sciences